Effects of Macuprev
Aged
Aged, 80 and over
Antioxidants
/ administration & dosage
Dietary Supplements
Double-Blind Method
Electroretinography
Female
Follow-Up Studies
Humans
Italy
Lutein
/ administration & dosage
Macular Degeneration
/ drug therapy
Male
Middle Aged
Prospective Studies
Retina
/ drug effects
Tomography, Optical Coherence
Visual Acuity
/ drug effects
Zeaxanthins
/ administration & dosage
Carotenoid and antioxidant supplementation
Intermediate age-related macular degeneration
OCT
Ophthalmology
mfERG
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
15
05
2019
pubmed:
28
6
2019
medline:
11
6
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
To evaluate the effects of Macuprev In this double-blind, monocentric, randomized, and prospective study, 30 patients with intermediate AMD were enrolled and randomly divided into two age-similar groups: 15 patients (AMD-M group; mean age 68.50 ± 8.79 years) received 6-month oral daily supplementation with Macuprev At 6-month follow-up, AMD-M eyes showed a significant increase of mfERG response amplitude density (RAD) recorded from the central macular areas (ring 1, 0-2.5°; ring 2, 2.5-5°), whereas non-significant changes of retinal and choroidal SD-OCT parameters were found when values were compared to baseline. Non-significant correlations between functional and structural changes were found. In AMD-P eyes, non-significant differences for each mfERG and SD-OCT parameters were observed at 6 months. In intermediate AMD, Macuprev ClinicalTrials.gov identifier, NCT03919019. Research for this study was financially supported by the Italian Ministry of Health and Fondazione Roma. Article processing charges were funded by Farmaplus Italia s.r.l., Italy.
Sections du résumé
BACKGROUND
To evaluate the effects of Macuprev
METHODS
In this double-blind, monocentric, randomized, and prospective study, 30 patients with intermediate AMD were enrolled and randomly divided into two age-similar groups: 15 patients (AMD-M group; mean age 68.50 ± 8.79 years) received 6-month oral daily supplementation with Macuprev
RESULTS
At 6-month follow-up, AMD-M eyes showed a significant increase of mfERG response amplitude density (RAD) recorded from the central macular areas (ring 1, 0-2.5°; ring 2, 2.5-5°), whereas non-significant changes of retinal and choroidal SD-OCT parameters were found when values were compared to baseline. Non-significant correlations between functional and structural changes were found. In AMD-P eyes, non-significant differences for each mfERG and SD-OCT parameters were observed at 6 months.
CONCLUSIONS
In intermediate AMD, Macuprev
TRIAL REGISTRATION
ClinicalTrials.gov identifier, NCT03919019.
FUNDING
Research for this study was financially supported by the Italian Ministry of Health and Fondazione Roma. Article processing charges were funded by Farmaplus Italia s.r.l., Italy.
Identifiants
pubmed: 31243641
doi: 10.1007/s12325-019-01016-2
pii: 10.1007/s12325-019-01016-2
pmc: PMC6822854
doi:
Substances chimiques
Antioxidants
0
Zeaxanthins
0
Lutein
X72A60C9MT
Banques de données
ClinicalTrials.gov
['NCT03919019']
figshare
['10.6084/m9.figshare.8243120']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2493-2505Commentaires et corrections
Type : ErratumIn
Références
Ophthalmology. 2008 Feb;115(2):324-333.e2
pubmed: 17716735
Eur J Ophthalmol. 2016 Mar-Apr;26(2):128-34
pubmed: 26350997
Br J Ophthalmol. 2015 Mar;99(3):371-5
pubmed: 25228440
Br J Ophthalmol. 2002 Jul;86(7):795-800
pubmed: 12084753
Retina. 2007 Sep;27(7):879-90
pubmed: 17891012
Mol Vis. 2011;17:1784-93
pubmed: 21753864
Am J Ophthalmol. 2015 Apr;159(4):617-26
pubmed: 25526948
Biochim Biophys Acta. 2005 May 30;1740(2):101-7
pubmed: 15949675
Am J Ophthalmol. 2017 Aug;180:55-63
pubmed: 28579063
Doc Ophthalmol. 2012 Feb;124(1):1-13
pubmed: 22038576
Invest Ophthalmol Vis Sci. 2012 Oct 09;53(11):6973-80
pubmed: 22969069
Invest Ophthalmol Vis Sci. 1988 Jun;29(6):843-9
pubmed: 3372161
Am J Ophthalmol. 2011 Dec;152(6):1030-1038.e2
pubmed: 21851922
Eye Vis (Lond). 2017 Oct 15;4:23
pubmed: 29046877
PLoS One. 2015 Oct 09;10(10):e0139257
pubmed: 26451726
Br J Ophthalmol. 2007 Mar;91(3):354-9
pubmed: 16973663
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Br J Nutr. 2013 Jun;109(11):2008-14
pubmed: 23084077
Eur J Ophthalmol. 2012 Mar-Apr;22(2):216-25
pubmed: 22009916
Ophthalmology. 2009 Mar;116(3):488-496.e2
pubmed: 19167082
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):563-70
pubmed: 24146272
Prog Retin Eye Res. 2000 Sep;19(5):607-46
pubmed: 10925245
Retina. 2020 Apr;40(4):632-642
pubmed: 30664125
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3976-83
pubmed: 26087362
Biotechnol Prog. 2016 Jan-Feb;32(1):5-13
pubmed: 26518672
Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3538-49
pubmed: 12407166
Graefes Arch Clin Exp Ophthalmol. 2001 Aug;239(8):556-61
pubmed: 11585310
JAMA. 2013 May 15;309(19):2005-15
pubmed: 23644932
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):360-71
pubmed: 26842754
JAMA. 1994 Nov 9;272(18):1413-20
pubmed: 7933422
Cell Mol Life Sci. 2016 May;73(9):1765-86
pubmed: 26852158
J Comp Neurol. 1990 Feb 22;292(4):497-523
pubmed: 2324310
Am J Ophthalmol. 2012 Oct;154(4):625-634.e1
pubmed: 22835510
Invest Ophthalmol Vis Sci. 1991 Feb;32(2):268-79
pubmed: 1993577
Eye (Lond). 2001 Jun;15(Pt 3):376-83
pubmed: 11450761
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1307-1314
pubmed: 30017190
Cochrane Database Syst Rev. 2012 Nov 14;11:CD000254
pubmed: 23152201
Semin Ophthalmol. 2018;33(4):461-469
pubmed: 28328288
Invest Ophthalmol Vis Sci. 1980 Aug;19(8):857-63
pubmed: 7409981
Doc Ophthalmol. 2016 Feb;132(1):17-26
pubmed: 26754967
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):235-40
pubmed: 11133874
Ophthalmology. 2013 Sep;120(9):1860-70
pubmed: 23642377
Doc Ophthalmol. 2016 Apr;132(2):123-35
pubmed: 26988845